 Phase 1 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat RefractoryRelapsed AML Patients Phase 1 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat RefractoryRelapsed AML Patients 